This drug repurposing analysis also identified the IL-6 receptor (IL6R) and IL17RA proteins as targets for the FDA-approved drugs Satralizumab and Brodalumab that are approved to treat autoimmune diseases such as neuromyelitis optica spectrum disorder (NMOSD) and severe plaque psoriasis, respectively. Here, IL6R is linked to psoriasis vulgaris.